Abstract 623P
Background
The mHSPC treatment landscape is rapidly evolving, most recently with the entry of second-generation anti-androgen receptor inhibitors (SGARIs). This study describes mHSPC patients’ demographic, clinical, physician characteristics, and current treatment patterns.
Methods
This cross-sectional, retrospective, chart review study included mHSPC patients (aged ≥ 18 years) in the US, Germany, France, Japan, and China from the IPSOS Global Oncology Monitor Database (2018-2020). Descriptive analyses were conducted for all study objectives.
Results
6,198 mHSPC patients were included; US (N=3893), Germany, (N=867), France, (N=513), Japan, (N=641), and China, (N=284). Patients were generally aged ≥70 years (69.5%), well-functioning (ECOG score 0-1: 83.3%), and most patients were treated by urologists (59.8%) without oncologist co-management. Patients in Europe (Germany, 69.4%; France, 76.6%) and the US (82.6%) were primarily treated with luteinizing hormone releasing hormone (LHRH) agonists, and in Asia, with a combination of LHRH agonist(s) (China, 71.8%; Japan, 82.6%) and first-generation (FG) ARIs (China, 74.6%; Japan, 70.8%). With the exception of France (38.6%), the majority of patients were treated with combination therapy (57.4%) across the remaining four markets. Across the five countries, use of androgen synthesis inhibitor (ASI) (14.3%) and SGARIs (5.6%) was relatively infrequent, but increasing over the study period, as measured in successive cross-sectional data cuts. Chemotherapy was used consistently across the study period, with more use in Europe and China (Germany, 17.0%; France, 15.0%; 13.4%) than in the US (8.5%) or Japan (0.2%).
Conclusions
LHRH agonists and FGARIs were used most commonly, while use of ASIs and SGARIs was in the single digits yet increasing. Differences in guideline evolution, regulatory approval and reimbursement during the study period likely explains some of the cross-country differences. In addition, the differences of disciplines involved in treatment may have an impact.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
OPEN Health.
Funding
Bayer Pharmaceuticals.
Disclosure
P.J. Goebell: Other, Institutional, Other, Honoraria: Astellas; Other, Institutional, Other, Honoraria: AstraZeneca; Other, Institutional, Other, Honoraria: Bayer; Other, Institutional, Other, Honoraria: BMS; Other, Institutional, Other, Honoraria: Eisai; Other, Institutional, Other, Honoraria: Ipsen; Other, Institutional, Other, Honoraria: Janssen; Other, Institutional, Other, Honoraria: Novartis; Other, Institutional, Other, Honoraria: Pfizer; Other, Institutional, Other, Honoraria: Roche; Other, Institutional, Other, Honoraria: Sanofi; Other, Institutional, Other, Travel, Accommodations, Expenses: Astellas; Other, Institutional, Other, Travel, Accommodations, Expenses: AstraZeneca; Other, Institutional, Other, Travel, Accommodations, Expenses: Bayer; Other, Institutional, Other, Travel, Accommodations, Expenses: BMS; Other, Institutional, Other, Travel, Accommodations, Expenses: Eisai; Other, Institutional, Other, Travel, Accommodations, Expenses: Ipsen; Other, Institutional, Other, Travel, Accommodations, Expenses: Janssen; Other, Institutional, Other, Travel, Accommodations, Expenses: Novartis; Other, Institutional, Other, Travel, Accommodations, Expenses: Pfizer; Other, Institutional, Other, Travel, Accommodations, Expenses: Roche; Other, Institutional, Other, Travel, Accommodations, Expenses: Sanofi; Other, Institutional, Advisory Role, Clinical and scientific advisor for the present study: Bayer. R. Shah: Financial Interests, Institutional, Funding, Ruchit Shah is an employee of OPEN Health Evidence and Access. OPEN Health Evidence and Access received funding from Merck and Co, Inc for conducting this study: Merck and Co, Inc. R. Raina: Financial Interests, Institutional, Full or part-time Employment: OPEN Health. S. Rege: Financial Interests, Institutional, Full or part-time Employment: OPEN Health Evidence and Access. S.L. Chen: Financial Interests, Personal, Full or part-time Employment: Bayer Healthcare Pharmaceuticals; Financial Interests, Institutional, Stocks/Shares: Bayer Healthcare Pharmaceuticals; Financial Interests, Institutional, Funding: Bayer Healthcare Pharmaceuticals. V.E. Lee: Financial Interests, Personal, Full or part-time Employment: Bayer Pharmaceuticals; Financial Interests, Personal, Stocks/Shares, Employee Shares: Bayer Pharmaceuticals. R. Waldeck: Financial Interests, Institutional, Full or part-time Employment: Bayer Pharmaceuticals; Financial Interests, Institutional, Stocks/Shares: Bayer Pharmaceuticals; Financial Interests, Institutional, Funding: Bayer Pharmaceuticals; Non-Financial Interests, Personal, Sponsor/Funding: European Cancer Organization.